<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Pawprint, Inc.

    Pawprint, Inc.

    Pawprint is an app that allows you to streamline communication between veterinaria...

    Pawprint is an app that allows you to streamlin...

    Amount Raised:    $142,647.00
    Fundraising Status:    EC
    Filing Type:    CF
    G1 Therapeutics, Inc.

    G1 Therapeutics, Inc.

    G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on th...

    G1 Therapeutics, Inc., is a clinical-stage biop...

    Filing Type:    PU
    RadNet, Inc.

    RadNet, Inc.

    RadNet is the national leader in outpatient imaging. Backed by 30 years of experie...

    RadNet is the national leader in outpatient ima...

    Filing Type:    PU
    Neurocarrus Inc

    Neurocarrus Inc

    Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet ne...

    Neurocarrus is developing a breakthrough therap...

    Amount Raised:    $344,168.00
    Fundraising Status:    EC
    Filing Type:    CF
    AnaptysBio, Inc.

    AnaptysBio, Inc.

    AnaptysBio is a clinical-stage antibody development company advancing therapeutic ...

    AnaptysBio is a clinical-stage antibody develop...

    Filing Type:    PU
    Alkermes plc

    Alkermes plc

    Alkermes plc is a fully integrated, global biopharmaceutical company developing in...

    Alkermes plc is a fully integrated, global biop...

    Filing Type:    PU
    Fate Therapeutics, Inc.

    Fate Therapeutics, Inc.

    We are a biopharmaceutical company dedicated to the development of programmed cell...

    We are a biopharmaceutical company dedicated to...

    Filing Type:    PU
    Dynavax Technologies Corporation

    Dynavax Technologies Corporation

    Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceuti...

    Dynavax Technologies Corporation (Nasdaq: DVAX)...

    Filing Type:    PU
    Check-Cap Ltd.

    Check-Cap Ltd.

    Check-Cap is a clinical-stage medical diagnostics company developing C-ScanÂŽ, the...

    Check-Cap is a clinical-stage medical diagnosti...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.